Requests that the FDA initiate all administrative and judicial action necessary to remove from the market, and to prevent the further marketing of lidocaine-containing drug products in patch, plaster, poultice, or comparable delivery systems that have not been approved pursuant to a new drug application or an abbreviated new drug application submitted under 21 U.S.C. § 355 and implementing